Altace Related Published Studies
Well-designed clinical trials related to Altace (Ramipril)
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. [2008.09]
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. [2008.08.16]
Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril-Hydrochlorothiazide Hypertension Trial. [2008.08]
The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure - a prospective, randomized, controlled prevention trial of the German Hypertension League. [2008.07]
Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril-Hydrochlorothiazide Hypertension Trial. [2008.05.08]
The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. [2008.05]
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. [2008.05]
Telmisartan, ramipril, or both in patients at high risk for vascular events. [2008.04.10]
[ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events] [2008.04]
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. [2008.03]
Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. [2008.03]
Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: a randomized cross-over study. [2008.02.19]
Modulation of pain perception by ramipril and losartan in human volunteers. [2008.01]
Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease. [2007.12.20]
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. [2007.12]
Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. [2007.12]
Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. [2007.09]
Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. [2007.09]
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). [2007.07]
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. [2007.06]
Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. [2007.06]
The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials. [2007.06]
Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. [2007.05.05]
Effect of ramipril on the incidence of diabetes. [2006.10.12]
Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. [2006.09.09]
The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure. [2006.09]
Effects of ramipril on renal function during progressive overpacing-induced heart failure in dogs. [2006.07]
Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) study. [2006.06]
Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. [2006.05.02]
Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. [2006.03]
Comparative bioavailability of two ramipril formulations after single-dose administration in healthy volunteers. [2006.02]
A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. [2006.01]
The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). [2006.01]
Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients. [2006]
Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. [2005.08.30]
The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study. [2005.06]
Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events. [2005.06]
Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. [2005.06]
Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. [2005.06]
Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. [2004.11]
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). [2004.10]
A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension. [2004.10]
Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product. [2004.10]
Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. [2004.09.14]
Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. [2004.08]
Simvastatin combined with ramipril treatment in hypercholesterolemic patients. [2004.08]
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. [2004.07]
Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. [2004.06.16]
Effect of ramipril on postrevascularization prevalence of angina and quality of life. [2004.06]
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). [2004.02.28]
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. [2004.01]
Lack of male-female differences in disposition and esterase hydrolysis of ramipril to ramiprilat in healthy volunteers after a single oral dose. [2003.12.11]
The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. [2003.03.04]
Ramipril for the prevention and treatment of cardiovascular disease. [2003.03]
Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. [2003.03]
Effect of long-term therapy with ramipril in high-risk women. [2002.08.21]
Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction. [2002.08]
The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study. [2002.06]
Use of ramipril in preventing stroke: double blind randomised trial. [2002.03.23]
Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. [2001.12.01]
Ramipril and the development of diabetes. [2001.10.17]
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. [2001.10.02]
Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. [2001.07.31]
Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy. [2001.07]
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. [2001.06.06]
Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular function and no clinical heart failure. [2001.04]
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). [2001.02.20]
Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients. [2001]
Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial. [2000.12]
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. [2000.08]
The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group. [2000.08]
Practice vs ambulatory blood pressure measurement under treatment with ramipril (PLUR Study): a randomised, prospective long-term study to evaluate the benefits of ABPM in patients on antihypertensive treatment. [2000.07]
Treatment of arterial hypertension in the elderly with diltiazem vs ramipril. [2000.06]
The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not. [2000.04]
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. [2000.01.20]
Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER. [1999.11]
ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patients with stable ischaemic heart disease and preserved left ventricular systolic function. [1999.11]
The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy. [1999.08]
The effects of ramipril on sympathetic nervous system function in older patients with hypertension. [1999.04]
Ramipril reduces QT dispersion in patients with acute myocardial infarction and heart failure. [1999.03.15]
Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. [1999.01]
Response of serum total renin to ramipril and metoprolol in hypertensive patients. [1998.12]
Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction. [1998.11]
Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. [1998.10.17]
Impediment of the progressions of microalbuminuria and hyperlipidemia in normotensive type 2 diabetes by low-dose ramipril. [1998.09]
Vagal cardiac activity in essential hypertension: the effects of metoprolol and ramipril. [1998.06]
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients. [1998.05]
Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine. [1998.01.31]
The Angiotensin Converting Enzyme Inhibition Post Revascularization Study (APRES). Effects of ramipril in patients with reduced left ventricular function. Rationale, design, methods, baseline characteristics and first-year experience. [1998]
A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two years. [1997.12]
Effect of ramipril on mitral regurgitation secondary to mitral valve prolapse. [1997.09.01]
Effect of ramipril on heart rate variability in digitalis-treated patients with chronic heart failure. [1997.09]
Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. [1997.07.15]
[Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study] [1997.06]
Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. [1997.05.24]
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. [1997.01]
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. [1996.12]
Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria. [1996.12]
Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE. [1996.10.15]
Efficacy of ramipril versus enalapril in patients with mild to moderate essential hypertension. [1996.09]
Effects of ramipril and enalapril on cerebral blood flow in elderly patients with asymptomatic carotid artery occlusive disease. [1996.07]
|
